Last reviewed · How we verify
Topical diclofenac sodium gel
Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.
Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application. Used for Localized musculoskeletal pain and inflammation, Osteoarthritis pain (topical), Rheumatoid arthritis pain (topical).
At a glance
| Generic name | Topical diclofenac sodium gel |
|---|---|
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 enzymes |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
As a nonsteroidal anti-inflammatory drug (NSAID), diclofenac blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. When applied topically as a gel, it penetrates local tissues to provide anti-inflammatory and analgesic effects with minimal systemic absorption, making it suitable for localized musculoskeletal and joint pain.
Approved indications
- Localized musculoskeletal pain and inflammation
- Osteoarthritis pain (topical)
- Rheumatoid arthritis pain (topical)
Common side effects
- Local skin irritation or rash
- Photosensitivity
- Pruritus at application site
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Home-Based Strategies for Knee Osteoarthritis (NA)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days. (PHASE1)
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)
- Effects of Exercise Versus Topical Agents on Knee Osteoarthritis (NA)
- Exercise vs. Topical Diclofenac vs. PRP (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: